

PRODUCT INFORMATION




BSA-Semaglutide Complex (1.67 mM)

Item No. 45552

Synonym: Bovine Serum Albumin-Semaglutide
Supplied as: 1.67 mM semaglutide:0.8 mM BSA (2:1 semaglutide:BSA) in 150 mM sodium chloride, pH 7.4
Storage: -80°C (as supplied)
Stability: ≥2 years
Item Origin: Animal/Bovine

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Image



BSA-Semaglutide Complex (1.67 mM) (Item No. 45552) binds GLP-1R. Using the GLP-1 Receptor (human) Reporter Assay Kit (Item No. 702940), HEK293T/17 cells were treated with either BSA-Semaglutide Complex (1.67 mM) (Item No. 45552) or Semaglutide (Item No. 40231) solubilized in DMSO and reporter SEAP activity was measured. Similar EC₅₀ values were observed for both semaglutide preparations.

Description

BSA-Semaglutide Complex (1.67 mM) is composed of semaglutide and fatty acid-free bovine serum albumin (BSA) at an approximately 2:1 molar ratio of semaglutide:BSA. It was prepared under sterile conditions, then filtered and aliquoted into sterile vials. *In vivo*, semaglutide binds to albumin, delaying its degradation and clearance and increasing its half-life while reducing the pool of free semaglutide available to bind to the glucagon-like peptide 1 receptor (GLP-1R).^{1,2} Cayman's BSA-Semaglutide Complex (1.67 mM) can be used for the delivery of semaglutide to cells in culture without the use of harsh reagents that may be needed to increase its solubility. Cayman's BSA-Semaglutide Complex (1.67 mM) is suitable for use in short- and long-term cell culture applications (25+ hours). For best results, it is recommended that this product be used in conjunction with Cayman's BSA Control for BSA-Fatty Acid Complexes (5 mM) (Item No. 29556), prepared with fatty acid-free BSA.

References

1. Lau, J., Bloch, P., Schäffer, L., *et al.* Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. *J. Med. Chem.* **58**(18), 7370-7380 (2015).
2. Nayak, S., Dessai, A.D., and Nayak, U.Y. Current trends in semaglutide therapy and strategies to improve its bioavailability. *Expert Opin. Drug Deliv.* **21**, 1-15 (2026).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/12/2026

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM